CARB-X will donate up to $2 million to the Jenner Institute (part of the University of Oxford) to produce a vaccine that prevents gonorrhoea.   The researchers will work alongside the Oxford Vaccine Group with the aim to develop a vaccine that will create immunity against gonorrhoea and prevent individuals from developing the disease. Furthermore, it intends to stop the spread of antibiotic resistance that is found in gonococcal bacteria.   The gonorrhoea vaccine (dmGC_0817560) contains blebs (fluid-filled blisters) from the outer surface of gonococcus, which is the Native Outer Membrane…

Diabetes gene therapy firm appoints two ex AveXis execs to its board. Meanwhile, there are high level changes at  Merck, AlloVir and Abeona Therapeutics. Sit back, relax, and enjoy reading BioProcess Insider’s Ins & Outs. Former founding chief science and chief finance officers at AveXis, Brian Kaspar and Thomas Dee will join Endsulin to help develop the firm’s gene therapy against Type 1 diabetes. Enduslin is a company that is solely targeting Type 1 diabetes (T1D) with a potential one-time…

GSK will manufacture up to 60 million doses of Novavax’ COVID-19 vaccine candidate, NVX-CoV2373 for distribution in the UK. GlaxoSmithKline (GSK) will provide fill-finish services for Novavax’ COVID-19 vaccine at its Barnard Castle facility in Durham, UK. A rapid tech-transfer between the two firms will begin immediately, with manufacturing expected to begin as early as May 2021. GSK will prepare vials of the final vaccine in the last stage of manufacturing and package them for distribution and use, with both…